If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for non-opioid pain treatments that could help quell the still raging opioid ...
Hosted on MSN20h
Supernus wins FDA approval for Parkinson’s pump on fourth trySupernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of ...
Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...
Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
The U.S. Food and Drug Administration has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine ...
The U.S. Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.
The small trial will help to establish whether kidneys from genetically modified pigs can be transplanted into people safely and effectively.
A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.
January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...
That’s because there is an inverse relationship between presidential approval ratings and the stock market, according to an analysis conducted by Ned Davis Research. Donald Trump’s approval ...
GRAFAPEX™ (treosulfan) with fludarabine is FDA-approved for AML and MDS patients undergoing alloHSCT, showing improved overall survival compared to busulfan. Common side effects include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback